.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AX23_Leriglitazone.Leriglitazone .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AX23_Leriglitazone.Leriglitazone| name: | Leriglitazone |
| ATC code: | A16AX23 | route: | oral |
| n-compartments | 1 |
Leriglitazone is a selective peroxisome proliferator-activated receptor gamma (PPARĪ³) agonist. It is under development primarily for the treatment of X-linked adrenoleukodystrophy (X-ALD) and other central nervous system disorders associated with neuroinflammation and metabolic dysfunction. As of June 2024, it is not yet approved for clinical use.
Pharmacokinetic parameters estimated for oral administration in healthy adult subjects based on typical small molecule PK and limited phase 1/2 data summaries available as per press releases and clinicaltrials.gov; no peer-reviewed, citable published PK model with detailed parameters available.